Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ch806
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ch806 is a chimeric monoclonal antibody that targets a unique epitope on the Epidermal Growth Factor Receptor (EGFR). It specifically binds to both the de2-7 EGFR variant (EGFRvIII) and overexpressed wild-type EGFR in tumors, but does not bind to normal tissue EGFR expressed at physiological levels. This tumor-specific targeting differentiates it from other anti-EGFR therapies and potentially avoids the normal tissue toxicity seen with other EGFR-targeting antibodies.
02
Targets
Beyond the preview
Go deeper on ch806.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ch806.